Articles by Kenji Watanabe
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
XtalPi and PharmaEngine's AI-discovered PRMT5 inhibitor PEP08 starts Phase I solid tumor trial, marking major milestone in synthetic lethality cancer treatment.
UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases
UCB's $2.2B acquisition of Candid Therapeutics brings novel T-cell engager technology for autoimmune diseases, marking major expansion beyond oncology applications.
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.
NAMSA and Lexitas Form Strategic Partnership for Comprehensive Ophthalmic Medical Device Development Services
NAMSA partners with Lexitas Pharma Services to offer end-to-end ophthalmic medical device development, creating single-source solution for sponsors.
Taimei Technology Debuts AI-Powered Clinical Trial Platform at BioKorea 2026
Taimei Technology showcases AI-driven drug development platform at BioKorea 2026, planning Korea market entry with advanced clinical research solutions.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.
Citius Oncology Ships First LYMPHIR International Order to Europe, Expanding Global Cancer Treatment Access
Citius Oncology ships first international LYMPHIR order to Europe through regional distribution partners, marking major milestone in global expansion.
MHRA post-Brexit drug approval: Market Impact on UK-EU Pharma Firms
This article examines how the MHRA's post-Brexit drug approval process affects UK-EU pharmaceutical firms, highlighting the implications for drugs like XYZ for chronic pain.
ANVISA Priority Review Program: Clinical Trial Approval Timelines for Strategic Diseases
The ANVISA Priority Review Program accelerates clinical trial approvals for critical diseases, enhancing patient access to innovative therapies.
COFEPRIS Guidelines Oncology: What You Need to Know About RWE Framework
Learn about COFEPRIS guidelines for oncology and the Real-World Evidence (RWE) framework essential for advancing cancer therapies.
ANVISA Regulatory Changes Brazil: Impact on Oncology & Infectious Disease Trials
This article examines the recent ANVISA regulatory changes in Brazil and their significant implications for oncology and infectious disease clinical trials.
FDA Accelerated Approval Oncology: Market Impact on Novel Therapies in 2026
This article examines the market impact of the FDA's Accelerated Approval pathway on novel oncology therapies, focusing on XYZ Drug's role in cancer treatment by 2026.
Arcera Life Sciences Partners with Fosun Pharma for Neurodegenerative Disease R&D Collaboration
Arcera Life Sciences and Fosun Pharma establish strategic framework for neurodegenerative disease research, licensing, and technology development.
SAHPRA Approval Trastuzumab Deruxtecan: What You Need to Know
SAHPRA has approved Trastuzumab Deruxtecan, a groundbreaking therapy for HER2-positive breast cancer, offering new hope for patients.
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Akso Health Group (NASDAQ: AHG) announces entry into brain-computer interface development, establishing R&D infrastructure for next-generation neurotechnology solutions.
IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal
IMG Pharmaceutical announces definitive agreement to acquire Matsumoto Pharmaceutical, expanding its presence in Japan's pharmaceutical manufacturing market.
NMPA Accelerated Approval Oncology: 2027 Market Analysis & Case Studies
This article delves into NMPA's accelerated approval process for oncology, featuring a 2027 market analysis and insightful case studies on drug XYZ-123.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
FDA Breakthrough Therapy Designation: Impact on Rare Disease Investment & Innovation
The FDA Breakthrough Therapy Designation accelerates drug development for rare diseases, enhancing investment and innovation in treatments like DMD.